Should Off-Label Drugs Be Included as Comparators in Pharmacoeconomic Studies? Surrey M. WaltonGlen T. Schumock Editorial 01 October 2014 Pages: 1035 - 1037
NICE, Social Values, and Balancing Objectivity and Equity Suzanne R. HillLeslie G. Olson Commentary 24 September 2014 Pages: 1039 - 1041
Some Inconsistencies in NICE’s Consideration of Social Values Mike PauldenJames F. O’MahonyChristopher McCabe Leading Article 22 August 2014 Pages: 1043 - 1053
Through a Glass Darkly: Economics and Personalised Medicine Alan HaycoxMunir PirmohamedSarah Richards Practical Application 14 August 2014 Pages: 1055 - 1061
Cost Effectiveness of Treatments for non-ST-segment elevation Acute Coronary Syndrome Fotini GialamaEvangelia MiloniNikos Maniadakis Systematic Review 01 August 2014 Pages: 1063 - 1078
Cost Effectiveness of Liraglutide in Type II Diabetes: A Systematic Review Patrick M. ZuegerNeil M. SchultzTodd A. Lee Systematic Review 23 July 2014 Pages: 1079 - 1091
The Health Economics of Bladder Cancer: An Updated Review of the Published Literature Christina YeungTuan DinhJoseph Lee Review Article 24 July 2014 Pages: 1093 - 1104
A Review of Approaches for the Management of Specialty Pharmaceuticals in the United States Bijal Nitin PatelPatricia R. Audet Review Article Open access 14 August 2014 Pages: 1105 - 1114
Preferences for Oral Anticoagulants in Atrial Fibrillation: a Best–Best Discrete Choice Experiment Peter GhijbenEmily LancsarSilva Zavarsek Original Research Article 16 July 2014 Pages: 1115 - 1127
Evaluating Disease-Modifying Agents: A Simulation Framework for Alzheimer’s Disease Shien GuoDenis GetsiosMaren Gaudig Original Research Article 15 August 2014 Pages: 1129 - 1139
The Problem of Embedded Decision Nodes in Cost-Effectiveness Decision Trees Manuel AriasFrancisco Javier Díez Research Letter 31 July 2014 Pages: 1141 - 1145